|
|
||||||||
TRANSLATIONAL AND CLINICAL RESEARCH |
1 San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET) and Vita Salute San Raffaele University, via Olgettina 58, 20132 Milan, Italy
2 San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), via Olgettina 58, 20132 Milan, Italy
3 Department of Morphophysiology, School of Veterinary Medicine, University of Turin, Grugliasco, Torino, Italy
4 Stem Cell Research Institute, San Raffaele Scientific Institute, Milan, Italy
5 Reproductive Technologies Laboratory, CIZ, Istituto Sperimentale Italiano Lazzaro Spallanzani, Cremona, Italy, and Dipartimento Clinico Veterinario, University of Bologna, Ozzano Emilia, Italy
6 Department of Microbiology & Molecular Medicine, Faculty of Medicine, University of Geneva, Switzerland
* To whom correspondence should be addressed. E-mail: naldini.luigi{at}hsr.it.
| Abstract |
|---|
The isolation of human embryonic and somatic stem cells of different types has made it possible to design novel gene and cell replacement therapies. Vectors derived from retro/lentiviruses are used to stably introduce genes into stem cells and their progeny. Yet, the permissivity to retroviral infection varies among cell types. We previously showed that hematopoietic stem cells are poorly permissive to HIV-derived vectors and that pharmacological inhibition of the proteasome strongly enhances gene transfer. Here we report that the proteasome limits lentiviral gene transfer in all stem cell types tested, including embryonic, mesenchymal and neural, both of human and mouse origin. Remarkably, this inhibitory activity was sharply reduced upon differentiation of the stem cells, suggesting that it represents a novel feature of the stem cell/immature progenitor phenotype. Proteasome-mediated inhibition was specific for lentiviral vectors and occurred at a post-entry infection step. It was not mediated by activation of NF-kB, a major signaling pathway modulated by the proteasome, and did not correlate with high proteasome activity. Interaction of the virion core with Cyclophilin A was required to maximize the effect of proteasome inhibitor on the infection pathway. These findings are relevant to uncover new mediators of HIV gene transfer and help designing more effective protocols for the genetic modification of stem cells.
______________________________________________________________________________
Author contributions: F.R.S.: conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing; A.G.: collection and assembly of data; P.C.: collection and assembly of data; M.N.: collection and assembly of data; M.S.: provision of study material; C.G.: provision of study material; J.L.: data interpretation; L.N.: conception and design, data analysis and interpretation, manuscript writing, final approval of manuscript.
Key Words. Lentiviral vectors, gene transfer, somatic stem cells, embryonic stem cells, proteasome, proteasome inhibitor
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |